Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that modify RNA expression
September 17, 2025
Skyhawk reports positive first results in Huntington's patients for oral drug
Skyhawk Therapeutics released its first trial data in Huntington’s disease patients on Wednesday, demonstrating early and competitive levels of efficacy in an area that’s seen a long list of failures by other drug developers.
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease
Skyhawk Therapeutics Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders
Skyhawk Therapeutics today announces a strategic research collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company.
